Adaptimmune announces favorable review of safety from one billion cell dose cohort
Adaptimmune announced favorable review of safety data from the second dose cohort of patients who received one billion transduced SPEAR T‑cells targeting MAGE-A10 in the NSCLC study. Based on these data, the Safety Review Committee has endorsed dose escalation to the third dose cohorts. July 18, 2018